Spots Global Cancer Trial Database for squamous cell carcinoma of the oral cavity
Every month we try and update this database with for squamous cell carcinoma of the oral cavity cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| TPF-Induction Chemotherapy of Oropharyngeal and Cavity of the Mouth Cancer | NCT01108042 | Oropharynx Canc... Squamous Cell C... | Taxotere, Cispl... | 18 Years - 80 Years | University of Jena | |
| Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | NCT00400205 | Squamous Cell C... Oral Cancer | Docetaxel Cisplatin 5-fluorouracil | 18 Years - | Emory University | |
| Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | NCT03370276 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... Head and Neck S... Squamous Cell C... Head and Neck C... | Nivolumab Cetuximab | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Safety Trial of IRESSA, Cisplatin and Radiation Therapy for Patients With Head and Neck Cancer | NCT00195078 | Head and Neck C... | ZD1839 (IRESSA) Cisplatin Radiation Thera... | 18 Years - | Weill Medical College of Cornell University | |
| Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | NCT03459729 | Squamous Cell C... | Antitumor B | 18 Years - | Medical College of Wisconsin | |
| Safety and Efficacy Study of GL-0817 (With Cyclophosphamide) for the Prevention of Recurrence of Squamous Cell Carcinoma of the Oral Cavity | NCT02873819 | Squamous Cell C... | GL-0817 Hiltonol Sargramostim cyclophosphamid... Placebo | 18 Years - | Gliknik Inc. | |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT04831450 | Head and Neck S... HNSCC Squamous Cell C... Squamous Cell C... Squamous Cell C... | Cemiplimab-Rwlc | 18 Years - | University of Miami | |
| Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity | NCT01265849 | Squamous Cell C... Squamous Cell C... | LI Cyclophosphamid... Indomethacin Zinc Surgery Cisplatin Radiotherapy | 18 Years - | CEL-SCI Corporation | |
| A Feasibility Study on the Use of F-18-FDG-PET and Optical Imaging in Evaluation of Radiation-induced Oral Mucositis | NCT01077869 | Squamous Cell C... Oropharynx Meta... Lymph Metastase... | endoscopic exam... FDG-PET | 18 Years - | University Hospital, Ghent | |
| CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer | NCT03721757 | Squamous Cell C... | Nivolumab, Surg... Nivolumab, Surg... | 18 Years - | The Clatterbridge Cancer Centre NHS Foundation Trust | |
| Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil | NCT00400205 | Squamous Cell C... Oral Cancer | Docetaxel Cisplatin 5-fluorouracil | 18 Years - | Emory University | |
| Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity | NCT02331875 | Squamous Cell C... | IPH2201 Standard Surger... Postsurgical Ad... | 18 Years - | Innate Pharma | |
| Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity | NCT01265849 | Squamous Cell C... Squamous Cell C... | LI Cyclophosphamid... Indomethacin Zinc Surgery Cisplatin Radiotherapy | 18 Years - | CEL-SCI Corporation | |
| Contribution of Residual Tumour DNA Testing on the Surgical Bed | NCT05934929 | Squamous Cell C... | Circulating tum... | 18 Years - | Centre Henri Becquerel | |
| De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT06030440 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Eliminating RT ... RT standard of ... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | NCT03459729 | Squamous Cell C... | Antitumor B | 18 Years - | Medical College of Wisconsin | |
| Antitumor-B KAC PK Study | NCT05452408 | Squamous Cell C... | Antitumor B KAC | 18 Years - | Medical College of Wisconsin | |
| Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity | NCT01636544 | Squamous Cell C... Leukoplakia Ora... | contralateral h... | 18 Years - | Institut Pasteur | |
| Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC | NCT05608369 | HPV-Related Squ... Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Cisplatin Radiation thera... Vorinostat | 18 Years - | Case Comprehensive Cancer Center | |
| Recurrence in Buccinator Muscle Excision With the Skin Versus Without the Skin in Buccal Squamous Cell Carcinoma | NCT03364166 | Squamous Cell C... | surgical excisi... | - | Cairo University | |
| Testing the Safety of Giving a Standard Dose of Radiation Over a Shorter Period of Time for Patients Who Had Surgery for Intermediate-Risk Head and Neck Cancer | NCT05540899 | Head and Neck C... Head and Neck S... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Hypofractionate... | 18 Years - 75 Years | American College of Radiology | |
| A Phase 1 Dose Escalation Study of GC4419 in Combination With Chemoradiation for Squamous Cell Cancer of the Head & Neck | NCT01921426 | Squamous Cell C... Squamous Cell C... | GC4419 | 18 Years - | Galera Therapeutics, Inc. | |
| Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study | NCT03575598 | Squamous Cell C... Squamous Cell C... Squamous Cell C... | Sitravatinib Nivolumab | 18 Years - | University Health Network, Toronto | |
| Phase 2 Trial of Maintenance Cemiplimab for Head and Neck Squamous Cell Carcinoma (HNSCC) | NCT04831450 | Head and Neck S... HNSCC Squamous Cell C... Squamous Cell C... Squamous Cell C... | Cemiplimab-Rwlc | 18 Years - | University of Miami | |
| Infectious Aetiology of Potentially Malignant Disorders and Squamous Cell Carcinomas of the Oral Cavity | NCT01636544 | Squamous Cell C... Leukoplakia Ora... | contralateral h... | 18 Years - | Institut Pasteur | |
| Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer | NCT03459729 | Squamous Cell C... | Antitumor B | 18 Years - | Medical College of Wisconsin | |
| De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck | NCT06030440 | Squamous Cell C... Squamous Cell C... Squamous Cell C... Squamous Cell C... | Eliminating RT ... RT standard of ... | 18 Years - | University of Erlangen-Nürnberg Medical School | |
| CA209-891: Neoadjuvant and Adjuvant Nivolumab as Immune Checkpoint Inhibition in Oral Cavity Cancer | NCT03721757 | Squamous Cell C... | Nivolumab, Surg... Nivolumab, Surg... | 18 Years - | The Clatterbridge Cancer Centre NHS Foundation Trust | |
| Contribution of Residual Tumour DNA Testing on the Surgical Bed | NCT05934929 | Squamous Cell C... | Circulating tum... | 18 Years - | Centre Henri Becquerel |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
